<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614418</url>
  </required_header>
  <id_info>
    <org_study_id>HKU_WKL_RFA1</org_study_id>
    <nct_id>NCT01614418</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation for Gastric Metaplasia and Dysplasia</brief_title>
  <official_title>Endoscopic Radiofrequency Ablation for Gastric Metaplasia and Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric intestinal metaplasia (IM) and dysplasia, also referred to as intra-epithelial
      neoplasia, are well recognized precursors of gastric cancer. Apart from endoscopic
      surveillance, there is no other intervention which predictably eradicates pre-cancerous
      gastric lesions.

      Endoscopic radiofrequency ablative (RFA) therapy has been recently shown to be highly
      effective in eradicating both IM and dysplasia in patients with Barrett's esophagus. However,
      the potential role of RFA to remove gastric IM and dysplasia remains unknown. In this study,
      we determine the feasibility of using endoscopic RFA in treating early gastric neoplasia
      (metaplasia and dysplasia). Patients with gastric metaplasia and/or dysplasia will be treated
      with endoscopic RFA. The safety and effects of RFA will be determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological clearance of dysplasia/metaplasia</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>up to 6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Gastric Dysplasia</condition>
  <condition>Intestinal Metaplasia</condition>
  <arm_group>
    <arm_group_label>Endoscopic radiofrequency ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic radiofrequency ablation using BARRX HALO90 catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic radiofrequency ablation catheter</intervention_name>
    <description>Endoscopic radiofrequency ablation</description>
    <arm_group_label>Endoscopic radiofrequency ablation</arm_group_label>
    <other_name>BARRX HALO90</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological confirmation of gastric IM or dysplasia.

          2. The lesion is no larger than 5 cm in diameter.

          3. Age â‰¥ 18 years.

          4. No previous endoscopic mucosal resection or submucosal dissection.

          5. No active H. pylori infection.

          6. Subject is able to tolerate endoscopy and sedation.

          7. Subject agrees to participate, fully understands content of the informed consent, and
             signs the informed consent form.

        Exclusion Criteria:

          1. Gastric cancer (intra-mucosal cancer or worse).

          2. Prior gastric irradiation or surgery.

          3. Anti-platelet or anti-thrombotic medication use that cannot be stopped for 7 days
             before and after RFA.

          4. Gastric ulcers, fistulae and varices.

          5. History of alcohol and/or controlled substance dependency.

          6. Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wai Keung Leung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <zip>0</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>LEUNG Wai Keung</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

